A Phase 2 interventional study of cytisinicline and Placebo in Vaping and E-Cig Use, sponsored by Achieve Life Sciences. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-14.
Sponsored by Achieve Life Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 287 studies in Vaping with a site in United States — 65 open to participants now, 73 under way, 1 of them phase 3. Vaping · United States.
Among the 287 studies in Vaping with a site in United States, this one is the 79th largest by enrollment of the 257 interventional ones that give a count, is one of 33 that started in 2022, is one of 18 in phase 2, and was the 161st registered.
403 studies on the registry are indexed under Vaping; 96 are open to participants now.
Browse Vaping studies →65 of the 287 studies in Vaping with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 21+ · Healthy volunteers
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
Massachusetts General Hospital · Sites in United States
Ages 18–65
University of Nebraska · Sites in United States
Ages 15–18
Prisma Health-Upstate · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 64 Vaping studies recruiting now, 32 (50%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
287 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 21 · Phase 3 4 · Phase 4 12
First in 2013; this study’s year is marked. 33 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 80 across 323 interventional studies indexed under Vaping.
Median enrollment 71 across the 257 interventional studies, 110 across the 30 observational. Of the 202 that completed or were terminated, 87 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 287 have an industry lead sponsor. The 10 most frequent:
Achieve Life Sciences is the lead sponsor of 31 studies on the registry; 1 is open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 8 (67%) have results posted.
Achieve Life Sciences has 2 studies filed under Vaping — fewer than ten, so there is no comparison to draw.
30 of the studies in Vaping with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06159608Anna Stanhewicz, PhDSex Differences in the Vascular Effects of E-cigarette Use | 2026-12 |
| NCT04661683University of California, Los AngelesSecondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol | 2026-12-15 |
| NCT07553585Yale UniversitySurvey to Test the Nicotine Concentration and Nicotine Flux Labels for E-cigarettes | 2026-12-15 |
| NCT04907136Florida International UniversityDeveloping and Testing Health Warning Labels on the ENDS Device | 2026-12-30 |
Add all 30 to your calendar (.ics) → With an account.
Among the 287 studies in Vaping with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This placebo-controlled Phase 2 study is being conducted at sites within the United States to evaluate the efficacy and safety profile of 3 mg cytisinicline administered TID for 12 weeks for vaping cessation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
one placebo tablet orally (PO) three times daily (TID) plus behavioral support for 12 weeks
Drug: Placebo · Behavioral: Behavioral support
one cytisinicline tablet PO TID plus behavioral support for 12 weeks
Drug: cytisinicline · Behavioral: Behavioral support
film-coated oral tablets containing 3 mg cytisinicline
Also known as: cytisine
film-coated oral tablets containing matched placebo
Behavioral support sessions by a qualified study site staff member will be participant-driven and will include direct engagement with the participant about their attempt to quit vaping. Each session will last approximately 10 minutes.
Percentage of Participants With Vaping Abstinence From Week 9 to 12
Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.
Time frame: Weeks 9 to 12
Percentage of Participants With Vaping Abstinence From Week 3 to 6
Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.
Time frame: Weeks 3 to 6
Percentage of Participants With Vaping Abstinence From Week 6 to 9
Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.
Time frame: Weeks 6 to 9
Percentage of Participants Who Achieve Vaping Abstinence at Each Visit From Week 2 and Week 12 (Seven-Day Point Prevalence Rates)
The 7-day point prevalence abstinence endpoints are binary (success, failure), defined at each of the following visits: Week 2 to Week 12. Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days.
Time frame: Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Changes From Baseline in Quantitative Cotinine Levels From Week 2 to Week 12
Changes in nicotine vaping measured by weekly quantitative cotinine levels from Week 2 to Week 12.
Time frame: Baseline, Weeks 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Percentage of Participants With Vaping Abstinence From Week 9 to 16
Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping. Measurements were Weekly from Week 9 to 12 and one month for Week 16.
Time frame: Weeks 9 to 16
| Milestone | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Started | 53 | 107 |
| Randomized and treated | 53 | 106 |
| Completed | 42 | 89 |
| Not completed | 11 | 18 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 4 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Lost to follow-up | 5 | 9 |
| Withdrew: Other, not specified | 1 | 4 |
Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.
| percentage of participants | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Percentage of Participants With Vaping Abstinence From Week 9 to 12 | 15.1 | 31.8 |
Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.
| percentage of participants | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Percentage of Participants With Vaping Abstinence From Week 3 to 6 | 15.1 | 24.3 |
Vaping abstinence verified weekly using quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping.
| percentage of participants | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Percentage of Participants With Vaping Abstinence From Week 6 to 9 | 17.0 | 30.8 |
The 7-day point prevalence abstinence endpoints are binary (success, failure), defined at each of the following visits: Week 2 to Week 12. Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping in the past 7 days.
| percentage of participants | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Week 2 | 7.5 | 14.0 |
| Week 3 | 22.6 | 33.6 |
| Week 4 | 24.5 | 49.5 |
| Week 5 | 28.3 | 42.1 |
| Week 6 | 24.5 | 41.1 |
| Week 7 | 22.6 | 48.6 |
| Week 8 | 24.5 | 43.0 |
| Week 9 | 24.5 | 42.1 |
| Week 10 | 28.3 | 41.1 |
| Week 11 | 24.5 | 37.4 |
| Week 12 | 22.6 | 38.3 |
Changes in nicotine vaping measured by weekly quantitative cotinine levels from Week 2 to Week 12.
| ng/mL | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Change at Week 2 | -148.800 ± 26.8978 | -181.306 ± 18.5332 |
| Change at Week 3 | -132.497 ± 26.8617 | -205.329 ± 18.5404 |
| Change at Week 4 | -128.581 ± 27.0594 | -202.672 ± 18.5403 |
| Change at Week 5 | -118.161 ± 26.9808 | -201.526 ± 18.6277 |
| Change at Week 6 | -117.008 ± 27.0665 | -196.960 ± 18.7278 |
| Change at Week 7 | -130.288 ± 27.5571 | -179.597 ± 18.6438 |
| Change at Week 8 | -113.940 ± 27.3551 | -192.048 ± 18.8551 |
| Change at Week 9 | -109.008 ± 27.6687 | -195.014 ± 18.8908 |
| Change at Week 10 | -133.935 ± 27.2633 | -196.615 ± 18.8600 |
| Change at Week 11 | -123.616 ± 27.3577 | -186.878 ± 18.8610 |
| Change at Week 12 | -110.402 ± 27.3577 | -167.731 ± 18.8932 |
Vaping abstinence used quantitative saliva cotinine levels at \< 10 ng/mL for biochemical verification and participants' self-report of no vaping. Measurements were Weekly from Week 9 to 12 and one month for Week 16.
| percentage of participants | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| Percentage of Participants With Vaping Abstinence From Week 9 to 16 | 13.2 | 23.4 |
Collected over up to Week 16 ±3 days. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo + Behavioral Support | 0/53 (0%) | 0/53 (0%) | 26/53 (49.1%) |
| Cytisinicline + Behavioral Support | 0/106 (0%) | 0/106 (0%) | 42/106 (39.6%) |
| Event | Placebo + Behavioral Support | Cytisinicline + Behavioral Support |
|---|---|---|
| COVID-19Infections and infestations | 7/53 | 4/106 |
| Abnormal dreamsPsychiatric disorders | 1/53 | 13/106 |
| NauseaGastrointestinal disorders | 6/53 | 5/106 |
| InsomniaPsychiatric disorders | 1/53 | 11/106 |
| HeadacheNervous system disorders | 5/53 | 7/106 |
| AnxietyPsychiatric disorders | 4/53 | 10/106 |
| FatigueGeneral disorders | 2/53 | 6/106 |
| Upper respiratory tract infectionInfections and infestations | 3/53 | 6/106 |
| Dry mouthGastrointestinal disorders | 2/53 | 2/106 |
| Urinary tract infectionInfections and infestations | 2/53 | 1/106 |
| Age, Continuous(years) | Placebo + Behavioral Support | Cytisinicline + Behavioral Support | Total |
|---|---|---|---|
| Mean | 33.5 ± 10.94 | 33.6 ± 11.15 | 33.6 ± 11.05 |
| Sex: Female, Male(Participants) | Placebo + Behavioral Support | Cytisinicline + Behavioral Support | Total |
|---|---|---|---|
| Female | 29 | 54 | 83 |
| Male | 24 | 53 | 77 |
| Ethnicity (NIH/OMB)(Participants) | Placebo + Behavioral Support | Cytisinicline + Behavioral Support | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 4 | 9 |
| Not Hispanic or Latino | 48 | 103 | 151 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Placebo + Behavioral Support | Cytisinicline + Behavioral Support | Total |
|---|---|---|---|
| Asian | 3 | 3 | 6 |
| Black or African American | 5 | 9 | 14 |
| White | 43 | 92 | 135 |
| Other, Not Specified | 2 | 3 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jul 2022 to primary completion in Feb 2023, 7 months.
Results were first posted in Jan 2026, 2 years 10 months after primary completion. A results delay was requested in Feb 2024.
Of 16 phase 2 interventional studies under Vaping, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cytisine